Geodon in Weight Loss Study for Bipolar Disorders
Condition: Bipolar Disorder
MeSH terms: Bipolar Disorder
Intervention: Ziprasidone/Geodon
Intervention description: Ziprasidone/Geodon
Intervention MeSH terms: Ziprasidone
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 25.0
Sex: All
Minimum age: 18 Years
Maximum age: 65 Years
Healthy volunteers: No

Summary:

      This research study is designed to determine if replacing your current antipsychotic and/or
      mood stabilizer with ziprasidone (Geodon) will impact weight. This research is being
      conducted because Geodon has a documented effect on mood. Additionally, we believe Geodon to
      be an effective medication for overweight or obese patients with bipolar disorder. There will
      be approximately 25 patients enrolled in this study.
    

Eligibility criteria:

        Inclusion Criteria:Patients will meet the following criteria to be eligible to participate
        in the study:

          -  Diagnosis of Bipolar Disorder Type I, Type II, or NOS treated in ongoing therapy with
             atypical antipsychotic(s) and/or mood stabilizer(s) that have been implicated in
             causing weight gain (i.e. lithium, valproate, olanzapine, risperidone, quetiapine,
             aripiprazole).

          -  Age 18-65 years old

          -  Males; or nonpregnant, nonlactating females who are postmenopausal, surgically
             sterilized, or using a barrier method of contraception and have a negative pregnancy
             test

          -  Initial body mass index e 30 kg/m2, or e 27 kg/m2 and demonstrating or receiving
             treatment for metabolic consequences of overweight (fasting total cholesterol e
             200mg/dL, fasting triglycerides e 250 mg/dL, or fasting blood glucose e 100 mg/dL).

          -  Stable medication regimen of at least one month

          -  Not have been hospitalized due to medical or psychiatric reasons during the past year
             from date of consent.

          -  Ability to understand and cooperate with study procedures

          -  Have signed a written informed consent prior to entering the study Exclusion
             Criteria:Patients may not participate in the study if they have any of the following
             conditions:

          -  One of the following DSM-IV Axis I diagnoses: delirium, dementia, amnestic and other
             cognitive disorders, schizophrenia, anorexia nervosa or bulimia, or substance abuse or
             dependence (active within the last month), abuse of illicit drugs (excluding
             marijuana) within the past month

          -  Antisocial personality disorder

          -  Medical complications of obesity such as diabetes, hypertension, hyperlipidemia, and
             cardiovascular disease unless followed by their own general medical practitioner who
             authorizes their participation in the trial, and continues to follow them medically
             and make necessary adjustments of concurrent antidiabetic, antihypertensive,
             antihyperlipidemic agents during the trial;

          -  Item 10 (Suicidal Thoughts) on the MADRS greater than or equal to 4

          -  Suicide attempt within the past three months

          -  Obesity of endocrine origin

          -  Seizure disorders

          -  Progressive neurologic or systemic disorders; HIV

          -  Other serious illnesses such as cardiac, hepatic (including cirrhosis), renal,
             respiratory, neurologic, or hematologic disease or glaucoma

          -  Hypothyroidism or hyperthyroidism unless adequately treated with TSH no more than 10%
             above or below the limits of the normal range.

          -  Administration of any investigational drug within 30 days prior to screening

          -  Allergy or hypersensitivity to ziprasidone

          -  Administration of clozapine in the prior three months

          -  Pregnancy within the past six months

          -  Patients will be discontinued from the study should they develop any significant
             adverse side effects that cannot be managed by dosage adjustment